KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Q4 2025 value amounting to $7.2 billion.

  • Regeneron Pharmaceuticals' Other Gross PP&E Adjustments rose 1370.21% to $7.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.2 billion, marking a year-over-year increase of 1370.21%. This contributed to the annual value of $7.2 billion for FY2025, which is 1370.21% up from last year.
  • As of Q4 2025, Regeneron Pharmaceuticals' Other Gross PP&E Adjustments stood at $7.2 billion, which was up 1370.21% from $6.3 billion recorded in Q4 2024.
  • In the past 5 years, Regeneron Pharmaceuticals' Other Gross PP&E Adjustments ranged from a high of $7.2 billion in Q4 2025 and a low of -$15.6 million during Q3 2022
  • Its 5-year average for Other Gross PP&E Adjustments is $4.7 billion, with a median of $5.2 billion in 2022.
  • Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first soared by 1324.78% in 2022, then skyrocketed by 1470.52% in 2023.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Other Gross PP&E Adjustments stood at $4.2 billion in 2021, then increased by 13.25% to $4.8 billion in 2022, then grew by 14.71% to $5.5 billion in 2023, then increased by 14.06% to $6.3 billion in 2024, then rose by 13.7% to $7.2 billion in 2025.
  • Its Other Gross PP&E Adjustments was $7.2 billion in Q4 2025, compared to $6.3 billion in Q4 2024 and $5.5 billion in Q4 2023.